Details
| Original language | English |
|---|---|
| Pages (from-to) | 84-90 |
| Number of pages | 7 |
| Journal | Journal of cystic fibrosis |
| Volume | 2 |
| Issue number | 2 |
| Early online date | 13 May 2003 |
| Publication status | Published - Jun 2003 |
Abstract
Background: The clinical course of cystic fibrosis (CF) shows considerable variation resulting in differences in health care utilisation. We investigated important clinical parameters and their relation to costs. Methods: We collected clinical parameters together with health care utilisation of a representative paediatric CF population (n=138 patients) attending Hanover Medical School over a period of 1 year. 49% of the patients were chronically infected with Pseudomonas aeruginosa. Costs were calculated on the basis of the annual individual health care utilisation from the perspective of health insurance. Results: Total annual expenditure per patient amounted to €23,989 (S.D. 18,026), with home drug treatment representing the most important single cost factor (47% of total costs). While costs rose with age and doubled in the first 18 years, they correlated foremost with P. aeruginosa airway colonisation status and lung function expressed as FEV1. Costs of patients with chronic P. aeruginosa infection were more than three times higher than of uninfected patients. Conclusions: Health care expenditures for patients with CF vary with the clinical course. The variation can be explained to a large extend by clinical parameters.
Keywords
- Costs, Cystic fibrosis, Health economics, Prevention, Pseudomonas aeruginosa
ASJC Scopus subject areas
- Medicine(all)
- Pediatrics, Perinatology, and Child Health
- Medicine(all)
- Pulmonary and Respiratory Medicine
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Journal of cystic fibrosis, Vol. 2, No. 2, 06.2003, p. 84-90.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Cost of care and clinical condition in paediatric cystic fibrosis patients
AU - Baumann, Ulrich
AU - Stocklossa, Christiane
AU - Greiner, Wolfgang
AU - von der Schulenburg, Johann Matthias Graf
AU - von der Hardt, Horst
N1 - Funding Information: This work was supported by a grant of the German Federal Ministry of Education, Science and Technology. This work was presented in part at the 24th European Cystic Fibrosis Conference in Vienna, 2001.
PY - 2003/6
Y1 - 2003/6
N2 - Background: The clinical course of cystic fibrosis (CF) shows considerable variation resulting in differences in health care utilisation. We investigated important clinical parameters and their relation to costs. Methods: We collected clinical parameters together with health care utilisation of a representative paediatric CF population (n=138 patients) attending Hanover Medical School over a period of 1 year. 49% of the patients were chronically infected with Pseudomonas aeruginosa. Costs were calculated on the basis of the annual individual health care utilisation from the perspective of health insurance. Results: Total annual expenditure per patient amounted to €23,989 (S.D. 18,026), with home drug treatment representing the most important single cost factor (47% of total costs). While costs rose with age and doubled in the first 18 years, they correlated foremost with P. aeruginosa airway colonisation status and lung function expressed as FEV1. Costs of patients with chronic P. aeruginosa infection were more than three times higher than of uninfected patients. Conclusions: Health care expenditures for patients with CF vary with the clinical course. The variation can be explained to a large extend by clinical parameters.
AB - Background: The clinical course of cystic fibrosis (CF) shows considerable variation resulting in differences in health care utilisation. We investigated important clinical parameters and their relation to costs. Methods: We collected clinical parameters together with health care utilisation of a representative paediatric CF population (n=138 patients) attending Hanover Medical School over a period of 1 year. 49% of the patients were chronically infected with Pseudomonas aeruginosa. Costs were calculated on the basis of the annual individual health care utilisation from the perspective of health insurance. Results: Total annual expenditure per patient amounted to €23,989 (S.D. 18,026), with home drug treatment representing the most important single cost factor (47% of total costs). While costs rose with age and doubled in the first 18 years, they correlated foremost with P. aeruginosa airway colonisation status and lung function expressed as FEV1. Costs of patients with chronic P. aeruginosa infection were more than three times higher than of uninfected patients. Conclusions: Health care expenditures for patients with CF vary with the clinical course. The variation can be explained to a large extend by clinical parameters.
KW - Costs
KW - Cystic fibrosis
KW - Health economics
KW - Prevention
KW - Pseudomonas aeruginosa
UR - http://www.scopus.com/inward/record.url?scp=0038309274&partnerID=8YFLogxK
U2 - 10.1016/S1569-1993(03)00024-9
DO - 10.1016/S1569-1993(03)00024-9
M3 - Article
C2 - 15463855
AN - SCOPUS:0038309274
VL - 2
SP - 84
EP - 90
JO - Journal of cystic fibrosis
JF - Journal of cystic fibrosis
SN - 1569-1993
IS - 2
ER -